巴克莱ETN+精选MLP ETNs ATMP 深 沪
等待开盘 09-26 09:30:00 美东时间
28.96
-0.070
-0.24%
华盛通- 最 高29.11
- 今 开28.78
- 成交量 3.57万股
- 最 低 28.78
- 昨 收 29.03
- 总市值 5.14亿
- 52周最高 31.0103
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 24.7891
- 委 比 0.00%
- 总股本 1776.23万
- 历史最高 31.0103
- 量 比 0.93
- 振 幅 1.14%
- 历史最低 -0.459
- 每 手 1
- 风险率 2.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多REGENXBIO Reveals FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II; PDUFA Date Extended To February 8, 2026
ROCKVILLE, Md., Aug. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License Application (BLA) for
08-19 05:04
Barclays Bank PLC Releases 2025 Interim Results
The latest announcement is out from Barclays ETN+ Select MLP ETN ( ($ATMP) ). B...
07-29 23:47
Barclays Modifies ETN Provisions with New Indenture
An announcement from Barclays ETN+ Select MLP ETN ( ($ATMP) ) is now available....
04-29 18:29
Ocugen aligns with FDA on confirmatory study for OCU410ST
Ocugen (NASDAQ:OCGN) said it has reached an alignment with the FDA for a Phase 2/3 pivotal confirmatory study that could be used to support a Biologics License Application for its gene therapy OCU410S...
02-27 22:54
Barclays Bank Files 2024 Annual Report with SEC
Barclays ETN+ Select MLP ETN ( ($ATMP) ) has issued an update. Barclays Bank PL...
02-14 22:57
Barclays Executes Supplemental Indenture for Debt Securities
Barclays ETN+ Select MLP ETN ( ($ATMP) ) has shared an announcement. Barclays B...
02-06 06:47
Ocugen gets positive EU opinion for ATMP classification for OCU400
Ocugen (NASDAQ:OCGN) said it has received a positive opinion from European Medicines Agency regulators for Advanced Therapy Medicinal Product classification for its gene therapy OCU400 in the treatmen...
02-04 01:25
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to le...
01-14 18:00
泽辉生物亏损加剧依赖外部研究：实验涉及伦理难题，还存对赌协议
来源：港湾商业观察 近期，泽辉生物科技有限公司（下称“泽辉生物”）赴港递交招股书，中金公司为保荐机构，国内运营主体为苏州泽辉生物科技有限公司。 ...
2024-11-21 08:20
Capricor wins key EU designations for the lead asset
Capricor Therapeutics (NASDAQ:CAPR) announced Wednesday that the European Medicines Agency has issued Orphan Drug and Advanced Therapy Medicinal Product designations for its lead asset, deramiocel. Th...
2024-11-20 23:45
